Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib as Maintenance Treatment in Extensive-Stage Small-Cell Lung Cancer (TIMES)
2014-002497-37Phase 2Terminated
- Sponsor
- Istituto Oncologico Veneto
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tivantinib in small cell lung cancer (SCLC), sponsored by Istituto Oncologico Veneto. Primary endpoint: Progression-free survival. Started Oct 2014; status: terminated.
02
Drugs
tivantinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2014-002497-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002497-37.